Focal Stroke

Endothelin-1 microinjections (ET-1): Stereotaxic microinjections of picomole quantities of ET-1 can produce defined cortical lesions that correlate with functional loss in specialized brain regions (e.g. unilateral forelimb motor representation area). Injection of ET-1 in the vicinity of the MCA will result in lesions comparable to those observed using the MCAo technique.

CNS|CRO Model Advantages & Differentiation

  • Intensive post-MCAo care results in a >90% survival rate (vs 40-50% in conventional models), allowing long-term neurobehavioural evaluation of a more clinically relevant post-stroke population;
  • Major improvements to the ET-1 technique provides a highly reproducible, predictable, and localized injury. Observations can be made up to 2 months post-stroke, thus increasing understanding of therapeutic intervention, and improving chances of detecting the benefits of restorative or rehabilitative therapies;
  • Models are relevant to common problems for post-stroke survivors, with the ability to evaluate in emotionality, cognition, sensorimotor deficits, and learning and memory function.

Printable Model Information Sheet
Focal Stroke Model Information Sheet

Please contact info@cnscro.com for further details.

Back to Top